Use of laparocentesis in the treatment of ascites in patients with liver cirrhosis
https://doi.org/10.29235/1814-6023-2021-18-3-362-374
Abstract
Ascites occurs in about 60 % of patients with cirrhosis within 10 years of diagnosis. Laparocentesis is the preferred first-line therapy in patients with cirrhosis and massive tense ascites, allowing more than 5–6 liters of ascitic fluid to be removed at one time. The search for informative prognostic factors and the development of a method for predicting unfavorable outcomes of repeated laparocenteses in patients with ascites are relevant to timely refer this contingent of patients to perform TIPS.
The purpose of the study was to develop and evaluate the diagnostic significance of a model for determining the probability of unfavorable outcomes of laparocentesis in patients with ascites on the background of liver cirrhosis.
The results of treatment of 99 patients with the ascitic syndrome associated with intrahepatic portal hypertension were studied. The multiple regression analysis using the binary response logit model was carried out to calculate the prediction models.
The analysis of the treatment results of patients with liver cirrhosis and ascites by the laparocentesis method revealed a number of factors that influence the onset of an unfavorable outcome. 2 models with the inclusion of initial variables are the most promising for forecasting. Model A includes: patient weight, serum-ascites total protein gradient, hyponatremia; model B: MELD-Na score, serum-ascitic total protein gradient, patient weight. The developed prediction method is highly informative, effective, easily applicable, and can be widely used in clinical practice.
The ability to predict an unfavorable outcome in patients with portal hypertension and ascites after laparocentesis allows for a personalized approach in the process of timely selection of more effective, but also more expensive treatment methods, such as TIPS, which will help us to increase the therapy effectiveness and the survival of this cohort of patients.
About the Authors
E. V. Mahiliavets
Grodno State Medical University
Belarus
Belarus
Eduard V. Mahiliavets – Ph. D. (Med.), Associate Professor, Head of the Department
80, Gorky Str., 230009, Grodno
Y. N. Bozhko
City Clinical Hospital No. 4
Belarus
Belarus
Yelena N. Bozhko – Head of the Department
89, Yanka Kupala Ave., 230026, Grodno
O. N. Mahiliavets
Grodno State Medical University
Belarus
Belarus
Olga N. Mahiliavets – Ph. D. (Med.), Associate Professor
80, Gorky Str., 230009, Grodno
References
1. Pose E., Cardenas A. Translating our current understanding of ascites management into new therapies for patients with cirrhosis and fluid retention. Digestive Diseases, 2017, vol. 35, no. 4, pp. 402−410. https://doi.org/10.1159/000456595
2. Garbuzenko D. V., Arefyev N. O. Current approaches to the management of patients with cirrhotic ascites. World Journal of Gastroenterology, 2019, vol. 25, no. 28, pp. 3738−3752. https://doi.org/10.3748/wjg.v25.i28.3738
3. Gallo A., Dedionigi C., Civitelli C., Panzeri A., Corradi C., Squizzato A. Optimal management of cirrhotic ascites: a review for internal medicine physicians. Journal of Translational Internal Medicine, 2020, vol. 8, no. 4, pp. 220−236. https://doi.org/10.2478/jtim-2020-0035
4. Fortune B., Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterology Report, 2017, vol. 5, no. 2, pp. 104−112. https://doi.org/10.1093/gastro/gox010
5. Salerno F., Guevara M., Bernardi M., Moreau R., Wong F., Angeli P., Garcia-Tsao G., Lee S. S. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver International, 2010, vol. 30, no. 7, pp. 937−947. https://doi.org/10.1111/j.1478-3231.2010.02272.x
6. Stundiene I., Sarnelyte Ju., Norkute A., Aidietiene S., Liakina V., Masalaite L., Valantinas J. Liver cirrhosis and left ventricle diastolic dysfunction: systematic review. World Journal of Gastroenterology, 2019, vol. 25, no. 32, pp. 4779−4795. https://doi.org/10.3748/wjg.v25.i32.4779
7. Bai M. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated metaanalysis. World Journal of Gastroenterology, 2014, vol. 20, no. 10, pp. 2704−2714. https://doi.org/10.3748/wjg.v20.i10.2704
8. Allegretti A. S., Ortiz G., Cui J., Wenger Ju., Bhan I., Chung R. T., Thadhani R. I., Irani Z. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. American Journal of Kidney Diseases, 2016, vol. 68, no. 3, pp. 381−391. https://doi.org/10.1053/j.ajkd.2016.02.041
9. García-Pagán J. C., Saffo S., Mandorfer M., Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Reports, 2020, vol. 2, no. 4, p. 100122. https://doi.org/10.1016/j.jhepr.2020.100122
10. Ruf A. E., Kremers W. K., Chavez L. L., Descalzi V. I., Podesta L. G., Villamil F. G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transplantation, 2005, vol. 11, no. 3, pp. 336−343. https://doi.org/10.1002/lt.20329
11. Heuman D. M., Abou-Assi S. G., Habib A., Williams L. M., Stravitz R. T., Sanyal A. J., Fisher R. A., Mihas A. A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology, 2004, vol. 40, no. 4, pp. 802–810. https://doi.org/10.1002/hep.1840400409
12. Guevara M., Crdenas A., Urz J., Gins P. Prognosis in patients with cirrhosis and ascites. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment. Malden, Blackwell, 2005, pp. 260−270.
13. Arvaniti V., D’Amico G., Fede G., Manousou P., Tsochatzis E., Pleguezuelo M., Burroughs A. K. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology, 2010, vol. 139, no. 4, pp. 1246−1256.e5. https://doi.org/10.1053/j.gastro.2010.06.019
14. Guillaume M., Robic M.-A., Péron J.-M., Selves J., Otal Ph., Sirach E., Vinel J.-P., Bureau Ch. Clinical characteristics and outcome of cirrhotic patients with high protein concentrations in ascites: a prospective study. European Journal of Gastroenterology and Hepatology, 2016, vol. 28, no. 11, pp. 1268–1274. https://doi.org/10.1097/meg.0000000000000697
15. Urrunaga N. H., Singal A. G., Cuthbert J. A., Rockey D. C. Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. Journal of Hepatology, 2013, vol. 58, no. 6, pp. 1113−1118. https://doi.org/10.1016/j.jhep.2013.01.015
16. Barosa RRamos., L. R., Patita M., Nunes G., Fonseca J. CLIF-C ACLF score is a better mortality predictor than MELD, MELD-Na and CTP in patients with Acute on chronic liver failure admitted to the ward. Revista Española de Enfermedades Digestivas, 2017, vol. 109, pp. 399−405. https://doi.org/10.17235/reed.2017.4701/2016
17. Wang R., Qi X., Guo X. Quantification of ascites based on abdomino-pelvic computed tomography scans for predicting the in-hospital mortality of liver cirrhosis. Experimental and Therapeutic Medicine, 2017, vol. 14, pp. 5733−5742. https://doi.org/10.3892/etm.2017.5321
18. Elsabaawy M. M., Abdelhamid Sh. R., Alsebaey A., Abdelsamee E., Obada M. A., Salman T. A., Rewisha E. The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction. Clinical and Molecular Hepatology, 2015, vol. 21, no. 4, pp. 365−371. https://doi.org/10.3350/cmh.2015.21.4.365
19. Sola-Vera J., Such J. Understanding the mechanisms of paracentesis-induced crculatory dysfunction. European Journal of Gastroenterology and Hepatology, 2004, vol. 16, no. 3, pp. 295−298. https://doi.org/10.1097/00042737-200403000-00008
20. Bernardi M., Caraceni P., Navickis R. J., Wilkes M. M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology, 2012, vol. 55, no. 4, pp. 1172–1181. https://doi.org/10.1002/hep.24786
21. Sahay M., Sahay R. Hyponatremia: a practical approach. Indian Journal of Endocrinology and Metabolism, 2014, vol. 18, no. 6, pp. 760−771. https://doi.org/10.4103/2230-8210.141320
22. Tzamaloukas A. H., Malhotra D., Rosen B. H., Raj D. S., Murata G. H., Shapiro J. I. Principles of management of severe hyponatremia. Journal of the American Heart Association, 2013, vol. 2, no. 4, p. e005199. https://doi.org/10.1161/jaha.113.000240
23. Ginès P., Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology, 2008, vol. 48, no. 3, pp. 1002−1010. https://doi.org/10.1002/hep.22418
24. Solà E., Watson H., Graupera I., Turón F., Barreto R., Rodríguez E., Pavesi M., Arroyo V., Guevara M., Ginès P. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. Journal of Hepatology, 2012, vol. 57, no. 6, pp. 1199−1206. https://doi.org/10.1016/j.jhep.2012.07.020
25. Guevara M., Baccaro M. E., Torre A., Gómez-Ansón B., Ríos J., Torres F. [еt al.]. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. American Journal of Gastroenterology, 2009, vol. 104, no. 6, pp. 1382−1389. https://doi.org/10.1038/ajg.2009.293
26. Biggins S. W., Kim W. R., Terrault N. A., Saab S., Balan V., Schiano T. [еt al.]. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology, 2006, vol. 130, no. 6, pp. 1652−1660. https://doi.org/10.1053/j.gastro.2006.02.010
27. Londoño M. C., Guevara M., Rimola A., Navasa M., Taurà P., Mas A., García-Valdecasas J.-C., Arroyo V., Ginès P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology, 2006, vol. 130, no. 4, pp. 1135−1143. https://doi.org/10.1053/j.gastro.2006.02.017
28. Dawwas M. F., Lewsey J. D., Neuberger J. M., Gimson A. E. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transplantation, 2007, vol. 13, no. 8, pp. 1115−1124. https://doi.org/10.1002/lt.21154
29. Kim W. R., Biggins S. W., Kremers W. K., Wiesner R. H., Kamath P. S., Benson J. T., Edwards E., Therneau T. M. Hyponatremia and mortality among patients on the liver-transplant waiting list. New England Journal of Medicine, 2008, vol. 359, no. 10, pp. 1018−1026. https://doi.org/10.1056/nejmoa0801209
30. Rimola A., García-Tsao G., Navasa M., Piddock L. J. V., Planas R., Bernard B., Inadomi J. M. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology, 2000, vol. 32, no. 1, pp. 142−153. https://doi.org/10.1016/s0168-8278(00)80201-9
31. Angeleri A., Rocher A., Caracciolo B., Pandolfo M., Palaoro L., Perazzi B. New biochemical parameters in the differential diagnosis of ascitic fluids. Gastroenterology Research, 2016, vol. 9, no. 1, pp. 7−21. https://doi.org/10.14740/gr700w
32. Hanafy A. S. The role of ascitic fluid viscosity in differentiating the nature of ascites and in the prediction of renal impairment and duration of ICU stay. European Journal of Gastroenterology and Hepatology, 2016, vol. 28, no. 9, pp. 1021−1027. https://doi.org/10.1097/meg.0000000000000669
Review
For citations:
Mahiliavets E.V., Bozhko Y.N., Mahiliavets O.N. Use of laparocentesis in the treatment of ascites in patients with liver cirrhosis. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(3):362-374. (In Russ.) https://doi.org/10.29235/1814-6023-2021-18-3-362-374
Views: 866
Email this article 